Advertisement
| from breakthrough to blockbuster the business of biotechnology: From Breakthrough to Blockbuster Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos, 2022-02-14 Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. |
| from breakthrough to blockbuster the business of biotechnology: Science Business Gary P. Pisano, 2006 Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance. |
| from breakthrough to blockbuster the business of biotechnology: Science Lessons Gordon M. Binder, Philip Bashe, 2008 Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage. |
| from breakthrough to blockbuster the business of biotechnology: Biotechnology Entrepreneurship Craig Shimasaki, 2014-04-08 As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts |
| from breakthrough to blockbuster the business of biotechnology: Building Global Biobrands Françoise Simon, Philip Kotler, 2003 Two foremost marketing strategists combine their expertise in the first ever book to offer cutting-edge global strategies for marketing biotechnology. 20 charts & graphs. |
| from breakthrough to blockbuster the business of biotechnology: The Antidote Barry Werth, 2014-02-04 In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Journalist Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell the story of Vertex's bold endurance and eventual success. The pharmaceutical business is America's toughest and one of its most profitable. It's riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine; to the multibillion-dollar cost of ramping up a successful product; to operating in the world's most regulated industry, matched only by nuclear power. Werth captures the full scope of Vertex's 25-year drive to deliver breakthrough medicines.--From publisher description. |
| from breakthrough to blockbuster the business of biotechnology: Being A Biomedical Entrepreneur - Growth Of The Biomedical Industry Jen-shih Lee, 2018-12-06 This book is about the great innovations that the biomedical industry has had on improving the health and treating diseases of people and the incredible effort that scientists, engineers, technologists, mathematicians and physicians has invested in conceptualizing, producing and marketing the innovations. This rapidly growing industry is a knowledge intensive industry that is constantly generating, and adapting to, new technology. The innovations are the movers leading to the growth of the biomedical industry since 1960. However, its growth may be threatened by the lack of access to capital, a burdensome and uncertain regulatory environment, and lack of R&D innovation and productivity.It is written for students and professionals in science, technology, engineering, mathematics and medicine wanting to become a successful biomedical entrepreneur and to grow the biomedical industry. This book covers these four sectors of biomedical industries: medical technologies, healthcare information technology, pharmaceutic industry and biotech.Many innovations are employed throughout the book to make this book as a resource of use to help you invent, evaluate, develop and market your innovative products. Part I examines the education merits of biomedical engineers and teaches biomedical professionals to conceptualize their innovations and to assess whether their innovations could be manufactured and be wanted by patients. Part II will guide budding entrepreneurs to form the company and entrepreneurial team, to raise venture capital, to patent your innovative products, to obtain regulatory approval and to write your business plan. Other important aspects of company operations like financing, negotiations, leadership, manufacturing, marketing and globalization are covered in Part III. Two concluding chapters, with excerpts from leaders in community, education and industries, touch on the development, growth and investment of biomedical entrepreneurs on the delivery of better healthcare and economy to all people in the world. |
| from breakthrough to blockbuster the business of biotechnology: Genentech Sally Smith Hughes, 2011-09-21 In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it. |
| from breakthrough to blockbuster the business of biotechnology: From Alchemy To Ipo Cynthia Robbins-roth, 2000-05-18 A fascinating glimpse inside the life-and-death business of biotechnology. |
| from breakthrough to blockbuster the business of biotechnology: The Billion-Dollar Molecule Barry Werth, 2013-08-20 Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing—atom by atom—both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS. |
| from breakthrough to blockbuster the business of biotechnology: The Biotech Investor's Bible George Wolff, 2001-06-13 A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors. |
| from breakthrough to blockbuster the business of biotechnology: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| from breakthrough to blockbuster the business of biotechnology: Leading Pharmaceutical Innovation Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz, 2013-06-05 Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche. |
| from breakthrough to blockbuster the business of biotechnology: The Pharmagellan Guide to Biotech Forecasting and Valuation Frank S. David, Seth Robey, Andrew Matthews, 2017-01-06 If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. The Pharmagellan Guide is a comprehensive, thoroughly referenced handbook for early-stage biopharma assets and companies. |
| from breakthrough to blockbuster the business of biotechnology: Forecasting for the Pharmaceutical Industry Arthur G. Cook, 2016-03-03 Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making. In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex ’black box’ equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. The text is liberally illustrated with tables, diagrams and examples. The final extended case study provides the reader with an opportunity to test out their knowledge. The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars. |
| from breakthrough to blockbuster the business of biotechnology: The BioTech Primer BioTech Primer Inc., Emily Burke (Scientist.), 2012-06-18 THE BIOTECH PRIMER takes an in-depth look at the biotech industry, and in particular, the science that drives it. From cell structure to protein structure; gene expression to genetic variation and genetic engineering; the human immune response to the production of antibodies for biotech application; and finally drug discovery, drug development, and biomanufacturing-we discuss the key concepts and technologies that impact current biotechnology developments. This book will support your growth as a biotechnology professional. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come-and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends.More than anything else, we hope that your understanding of the science behind biotechnology will serve to increase your enthusiasm for this exciting and truly life-changing industry. The future is here-be a part of it. |
| from breakthrough to blockbuster the business of biotechnology: Future Prospects for Industrial Biotechnology OECD, 2011-09-16 This publication examines the international drivers, the enabling technologies that are fast-tracking Industrial Biotechnology, industry trends, some of the products that are appearing on the market, industry structure and finance, and finally policy measures and trends. |
| from breakthrough to blockbuster the business of biotechnology: In Sight Julia Levy, 2020-10-01 In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory research to its application as a medical treatment for vision loss. Told from a female perspective, In Sight is a unique and personal story covering Levy’s early years as a refugee, her university training in the UK, and her appointment as professor at the University of British Columbia. Years spent as an academic led the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Inc. The bulk of the book covers the years spent building the company, and Levy’s surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community. |
| from breakthrough to blockbuster the business of biotechnology: Biotechnology from A to Z William Bains, 1998 This book, now in its second edition, is an entertaining and practical introduction to the ideas and terminology of biotechnology. It uses straightforward language and real examples to unravel the jargon for the non-specialist and explains over 1000 terms in 250 short entries. This book is anaccessible guide to the science, technology and the real achievements of this fascinating and controversial industry. |
| from breakthrough to blockbuster the business of biotechnology: The Amgen Story Amgen Inc. (Thousand Oaks, Calif.), David Ewing Duncan, 2005 As the most successful biotech company in history and the eighth largest drug-producing company in the world, Amgen has improved the lives of millions of patients worldwide. In 2005, the company celebrates its twenty-fifth anniversary with the publication of The Amgen Story. This stunning illustrated book contains hundreds of archival photos and compelling text from noted biotech writer David Ewing Duncan. It is testament and tribute to the staff, leaders, patients, and science that make each discovery possible. |
| from breakthrough to blockbuster the business of biotechnology: Valuation in Life Sciences Boris Bogdan, Ralph Villiger, 2010-04-19 Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines. |
| from breakthrough to blockbuster the business of biotechnology: Troublemakers Leslie Berlin, 2017-11-07 Acclaimed historian Leslie Berlin’s “deeply researched and dramatic narrative of Silicon Valley’s early years…is a meticulously told…compelling history” (The New York Times) of the men and women who chased innovation, and ended up changing the world. Troublemakers is the gripping tale of seven exceptional men and women, pioneers of Silicon Valley in the 1970s and early 1980s. Together, they worked across generations, industries, and companies to bring technology from Pentagon offices and university laboratories to the rest of us. In doing so, they changed the world. “In this vigorous account…a sturdy, skillfully constructed work” (Kirkus Reviews), historian Leslie Berlin introduces the people and stories behind the birth of the Internet and the microprocessor, as well as Apple, Atari, Genentech, Xerox PARC, ROLM, ASK, and the iconic venture capital firms Sequoia Capital and Kleiner Perkins Caufield & Byers. In the space of only seven years, five major industries—personal computing, video games, biotechnology, modern venture capital, and advanced semiconductor logic—were born. “There is much to learn from Berlin’s account, particularly that Silicon Valley has long provided the backdrop where technology, elite education, institutional capital, and entrepreneurship collide with incredible force” (The Christian Science Monitor). Featured among well-known Silicon Valley innovators are Mike Markkula, the underappreciated chairman of Apple who owned one-third of the company; Bob Taylor, who masterminded the personal computer; software entrepreneur Sandra Kurtzig, the first woman to take a technology company public; Bob Swanson, the cofounder of Genentech; Al Alcorn, the Atari engineer behind the first successful video game; Fawn Alvarez, who rose from the factory line to the executive suite; and Niels Reimers, the Stanford administrator who changed how university innovations reach the public. Together, these troublemakers rewrote the rules and invented the future. |
| from breakthrough to blockbuster the business of biotechnology: Pharmaceutical Biotechnology Daan J. A. Crommelin, Robert D. Sindelar, 2002-11-14 The field of pharmaceutical biotechnology is evolving rapidly. A whole new arsenal of protein pharmaceuticals is being produced by recombinant techniques for cancer, viral infections, cardiovascular and hereditary disorders, and other diseases. In addition, scientists are confronted with new technologies such as polymerase chain reactions, combinatorial chemistry and gene therapy. This introductory textbook provides extensive coverage of both the basic science and the applications of biotechnology-produced pharmaceuticals, with special emphasis on their clinical use. Pharmaceutical Biotechnology serves as a complete one-stop source for undergraduate pharmacists, and it is valuable for researchers and professionals in the pharmaceutical industry as well. |
| from breakthrough to blockbuster the business of biotechnology: Real World Drug Discovery Robert M. Rydzewski, 2010-07-07 Drug discovery increasingly requires a common understanding by researchers of the many and diverse factors that go into the making of new medicines. The scientist entering the field will immediately face important issues for which his education may not have prepared him: project teams, patent law, consultants, target product profiles, industry trends, Gantt charts, target validation, pharmacokinetics, proteomics, phenotype assays, biomarkers, and many other unfamiliar topics for which a basic understanding must somehow be obtained. Even the more experienced scientist can find it frustratingly difficult to get an overview of the many factors involved in modern drug discovery and often only after years of exploring does a whole and integrated picture emerge in the mind of the researcher.Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research presents this kind of map of the landscape of drug discovery. In a single, readable volume it outlines processes and explains essential concepts and terms for the recent science graduate wondering what to expect in pharma or biotech, the medicinal chemist seeking a broader and more timely understanding of the industry, or the contractor or collaborator whose understanding of the commercial drug discovery process could increase the value of his contribution to it. - Interviews with well-known experts in many of the fields involved, giving insightful comments from authorities on many of the sub-disciplines important to cutting edge drug discovery. - Helpful suggestions gleaned from years of experience in biotech and pharma, which represents a repository drug discovery lore not previously available in any book. - Periodic Table of Drugs listing current top-selling drugs arranged by target and laid out so that structural similarities and differences are plain and clear. - Extensive use of diagrams to illustrate concepts like biotech startup models, preteomic profiling for target identification, Gantt charts for project planning, etc. |
| from breakthrough to blockbuster the business of biotechnology: The Price of Global Health Ed Schoonveld, 2011 The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. |
| from breakthrough to blockbuster the business of biotechnology: Rare Diseases and Orphan Products Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product Development, 2011-04-03 Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development. |
| from breakthrough to blockbuster the business of biotechnology: Industrial Biotechnology Wim Soetaert, Erick J. Vandamme, 2010-03-30 Describing all topics of white biotechnology admitted to the 7th EU Frame Programme and new industrial production processes aiming towards the Kyoto objectives, this comprehensive overview covers the technology, applications, economic potential and implications for society. Directed at readers with a general interest in a specific technology, this is equally suitable as an introductory handbook to a wide range of industries, including chemicals, biotechnology and pharmaceuticals, food and feed, paper and pulp, personal care, energy and agriculture. |
| from breakthrough to blockbuster the business of biotechnology: Leading Pharmaceutical Innovation Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer, 2018-05-10 Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. |
| from breakthrough to blockbuster the business of biotechnology: The Great American Drug Deal Peter Kolchinsky, 2020-01-20 Do we really have to choose between affordability of drugs and lifesaving innovation? No. In The Great American Drug Deal, Peter Kolchinsky offers clear-eyed analysis, compelling stories, and vital ideas for closing loopholes, dealing with bad actors, supporting patients, and fueling discoveries that ease suffering now and for generations to come. |
| from breakthrough to blockbuster the business of biotechnology: Continuous Manufacturing for the Modernization of Pharmaceutical Production National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, 2019-04-05 On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop. |
| from breakthrough to blockbuster the business of biotechnology: Biopunk Marcus Wohlsen, 2012-07-31 Bill Gates recently told Wired that if he were a teenager today, he would be hacking biology. If you want to change the world in some big way, he says, that's where you should start-biological molecules. The most disruptive force on the planet resides in DNA. Biotech companies and academic researchers are just beginning to unlock the potential of piecing together life from scratch. Champions of synthetic biology believe that turning genetic code into Lego-like blocks to build never-before-seen organisms could solve the thorniest challenges in medicine, energy, and environmental protection. But as the hackers who cracked open the potential of the personal computer and the Internet proved, the most revolutionary discoveries often emerge from out-of-the-way places, forged by brilliant outsiders with few resources besides boundless energy and great ideas. In Biopunk, Marcus Wohlsen chronicles a growing community of DIY scientists working outside the walls of corporations and universities who are committed to democratizing DNA the way the Internet did information. The biohacking movement, now in its early, heady days, aims to unleash an outbreak of genetically modified innovation by making the tools and techniques of biotechnology accessible to everyone. Borrowing their idealism from the worlds of open-source software, artisinal food, Internet startups, and the Peace Corps, biopunks are devoted advocates for open-sourcing the basic code of life. They believe in the power of individuals with access to DNA to solve the world's biggest problems. You'll meet a new breed of hackers who aren't afraid to get their hands wet, from entrepreneurs who aim to bring DNA-based medical tools to the poorest of the poor to a curious tinkerer who believes a tub of yogurt and a jellyfish gene could protect the world's food supply. These biohackers include: -A duo who started a cancer drug company in their kitchen -A team who built an open-source DNA copy machine -A woman who developed a genetic test in her apartment for a deadly disease that had stricken her family Along with the potential of citizen science to bring about disruptive change, Wohlsen explores the risks of DIY bioterrorism, the possibility of genetic engineering experiments gone awry, and whether the ability to design life from scratch on a laptop might come sooner than we think. |
| from breakthrough to blockbuster the business of biotechnology: Handbook of Industrial Chemistry and Biotechnology James A. Kent, 2013-01-13 Substantially revising and updating the classic reference in the field, this handbook offers a valuable overview and myriad details on current chemical processes, products, and practices. No other source offers as much data on the chemistry, engineering, economics, and infrastructure of the industry. The Handbook serves a spectrum of individuals, from those who are directly involved in the chemical industry to others in related industries and activities. It provides not only the underlying science and technology for important industry sectors, but also broad coverage of critical supporting topics. Industrial processes and products can be much enhanced through observing the tenets and applying the methodologies found in chapters on Green Engineering and Chemistry (specifically, biomass conversion), Practical Catalysis, and Environmental Measurements; as well as expanded treatment of Safety, chemistry plant security, and Emergency Preparedness. Understanding these factors allows them to be part of the total process and helps achieve optimum results in, for example, process development, review, and modification. Important topics in the energy field, namely nuclear, coal, natural gas, and petroleum, are covered in individual chapters. Other new chapters include energy conversion, energy storage, emerging nanoscience and technology. Updated sections include more material on biomass conversion, as well as three chapters covering biotechnology topics, namely, Industrial Biotechnology, Industrial Enzymes, and Industrial Production of Therapeutic Proteins. |
| from breakthrough to blockbuster the business of biotechnology: Modern Biopharmaceuticals, 4 Volume Set Jörg Knäblein, 2005-10-28 The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years. With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. |
| from breakthrough to blockbuster the business of biotechnology: Pharmaceutical Biotechnology Oliver Kayser, Heribert Warzecha, 2012-05-21 This second edition of a very successful book is thoroughly updated with existing chapters completely rewritten while the content has more than doubled from 16 to 36 chapters. As with the first edition, the focus is on industrial pharmaceutical research, written by a team of industry experts from around the world, while quality and safety management, drug approval and regulation, patenting issues, and biotechnology fundamentals are also covered. In addition, this new edition now not only includes biotech drug development but also the use of biopharmaceuticals in diagnostics and vaccinations. With a foreword by Robert Langer, Kenneth J Germeshausen Professor of Chemical and Biomedical Engineering at MIT and member of the National Academy of Engineering and the National Academy of Sciences. |
| from breakthrough to blockbuster the business of biotechnology: Cell Culture Engineering Wei-Shu Hu, 2006-08-16 Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade. |
| from breakthrough to blockbuster the business of biotechnology: Stem Cell Century Russell Korobkin, Stephen R. Munzer, 2007-01-01 Stem Cell Century provides a very clear analysis of the policy issues around cloning and stem cells in biomedicine, on the basis of a sound scientific understanding of the underlying biology. Ian Wilmut, director, Edinburgh University Centre for Regenerative Medicine, and creator of Dolly the lamb, the world's first cloned mammal. From the bookjacket. |
| from breakthrough to blockbuster the business of biotechnology: Introduction to Biological and Small Molecule Drug Research and Development C. Robin Ganellin, Roy Jefferis, Stanley M. Roberts, 2013-05-07 Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the book is actually put into practice. Studies include Herceptin/T-DM1, erythropoietin (Epogen/Eprex/NeoRecormon), anti-HIV protease inhibitor Darunavir, and more. Introduction to Biological and Small Molecule Drug Research and Development is intended for late-stage undergraduates or postgraduates studying chemistry (at the biology interface), biochemistry, medicine, pharmacy, medicine, or allied subjects. The book is also useful in a wide variety of science degree courses, in post-graduate taught material (Masters and PhD), and as basic background reading for scientists in the pharmaceutical industry. - For the first time, the fundamental scientific principles of biopharmaceuticals and small molecule chemotherapeutics are discussed side-by-side at a basic level - Edited by three senior scientists with over 100 years of experience in drug research who have compiled the best scientific comparison of small molecule and biopharmaceuticals approaches to new drugs - Illustrated with key examples of important drugs that exemplify the basic principles of pharmaceutical drug research and development |
| from breakthrough to blockbuster the business of biotechnology: Aspen Treatise for Patent Law Janice M. Mueller, 2024-07-19 A succinct, clearly written, first-principles demystification of U.S. patent law-- |
| from breakthrough to blockbuster the business of biotechnology: Biotechnology in the Time of COVID-19 Jeremy M. Levin, 2020-05-31 47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity. |
| from breakthrough to blockbuster the business of biotechnology: The Biotech Primer Emily Burke Ph D, 2019-11-05 The Biotech Primer takes an in-depth look at the biotech industry, and in particular, the science that drives it. From cell structure to protein structure; gene expression to genetic variation and genetic engineering; the human immune response to the production of antibodies for biotech application; and finally drug discovery, drug development, and biomanufacturing: we discuss the key concepts and technologies that impact current biotechnology developments. This book will support your growth as a biotechnology professional. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come: and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. More than anything else, we hope that your understanding of the science behind biotechnology will serve to increase your enthusiasm for this exciting and truly life-changing industry. The future is here and you should be a part of it. |
Breakthrough Cincinnati
WE ENERGIZE STUDENTS TO ENTER COLLEGE WITH CONFIDENCE & INSPIRE THE NEXT GENERATION OF EDUCATORS. Breakthrough Cincinnati is a four-year, tuition free college …
BREAKTHROUGH Definition & Meaning - Merriam-Webster
The meaning of BREAKTHROUGH is a sudden advance especially in knowledge or technique. How to use breakthrough in a sentence.
Summer 2025 — Breakthrough Cincinnati
Breakthrough Cincinnati. 6905 Given Rd. Cincinnati, OH 45243 513-370-5572 hello@breakthroughcincinnati.org . Scholars Teaching Fellows Donate. Breakthrough Cincinnati.
BRKTHROUGH | Immerse Yourself in Social Entertainment ...
Experience the ultimate in social entertainment at our 20,000 sq. ft. facility! Engage in team play as you tackle 40 unique challenge rooms, where mental prowess, physical agility, skill and …
Breakthrough (2019) - IMDb
Breakthrough: Directed by Roxann Dawson. With Marcel Ruiz, Topher Grace, Sarah Constible, Dennis Haysbert. When her 14-year-old son drowns in a lake, a faithful mother prays for him to …
Breakthrough (2019 film) - Wikipedia
Breakthrough is a 2019 American Christian drama film directed by Roxann Dawson in her feature film directorial debut. [3] The film was written by Grant Nieporte, based on the Christian book …
BREAKTHROUGH | English meaning - Cambridge Dictionary
BREAKTHROUGH definition: 1. an important discovery or event that helps to improve a situation or provide an answer to a…. Learn more.
Breakthrough Cincinnati
WE ENERGIZE STUDENTS TO ENTER COLLEGE WITH CONFIDENCE & INSPIRE THE NEXT GENERATION OF EDUCATORS. Breakthrough Cincinnati is a four-year, tuition free college …
BREAKTHROUGH Definition & Meaning - Merriam-Webster
The meaning of BREAKTHROUGH is a sudden advance especially in knowledge or technique. How to use breakthrough in a sentence.
Summer 2025 — Breakthrough Cincinnati
Breakthrough Cincinnati. 6905 Given Rd. Cincinnati, OH 45243 513-370-5572 hello@breakthroughcincinnati.org . Scholars Teaching Fellows Donate. Breakthrough Cincinnati.
BRKTHROUGH | Immerse Yourself in Social Entertainment ...
Experience the ultimate in social entertainment at our 20,000 sq. ft. facility! Engage in team play as you tackle 40 unique challenge rooms, where mental prowess, physical agility, skill and …
Breakthrough (2019) - IMDb
Breakthrough: Directed by Roxann Dawson. With Marcel Ruiz, Topher Grace, Sarah Constible, Dennis Haysbert. When her 14-year-old son drowns in a lake, a faithful mother prays for him to …
Breakthrough (2019 film) - Wikipedia
Breakthrough is a 2019 American Christian drama film directed by Roxann Dawson in her feature film directorial debut. [3] The film was written by Grant Nieporte, based on the Christian book …
BREAKTHROUGH | English meaning - Cambridge Dictionary
BREAKTHROUGH definition: 1. an important discovery or event that helps to improve a situation or provide an answer to a…. Learn more.
